In vitro analysis of replicative capacity and phenotypic susceptibility of integrase mutant HIV-2 viruses

被引：0
|
作者：
Le Hingrat, Q. [1 ]
Collin, G. [1 ]
Damond, F. [1 ]
Peytavin, G. [2 ]
Lebourgeois, S. [1 ]
Ghosn, J. [3 ]
Bachelard, A. [3 ]
Ferre, V. [1 ]
Matheron, S. [3 ]
Descamps, D. [1 ]
Charpentier, C. [1 ]
机构：
[1] Hop Bichat Claude Bernard, AP HP, Lab Virol, Paris, France
[2] Hop Bichat Claude Bernard, AP HP, Lab Pharmacol, Paris, France
[3] Hop Bichat Claude Bernard, AP HP, Serv Malad Infect & Trop, Paris, France
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
E13/27
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [21] HIV-2 Susceptibility to Entry Inhibitors
    Borrego, Pedro
    Taveira, Nuno
    AIDS REVIEWS, 2013, 15 (01) : 49 - 61
  • [22] Raltegravir resistance mutations affect strongly the integrase activities and the replicative capacity of viruses harbouring such mutations
    Marcelin, A. G.
    Malet, I.
    Delelis, O.
    Valantin, M. A.
    Montes, B.
    Tchertanov, L.
    Soulie, C.
    Wirden, M.
    Peytavin, G.
    Reynes, J.
    Katlama, C.
    Mouscadet, J. F.
    Calvez, V.
    ANTIVIRAL THERAPY, 2008, 13 (04) : A19 - A19
  • [23] In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
    Smith, Robert A.
    Raugi, Dana N.
    Pan, Charlotte
    Sow, Papa Salif
    Seydi, Moussa
    Mullins, James I.
    Gottlieb, Geoffrey S.
    RETROVIROLOGY, 2015, 12
  • [24] In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
    Robert A Smith
    Dana N Raugi
    Charlotte Pan
    Papa Salif Sow
    Moussa Seydi
    James I Mullins
    Geoffrey S Gottlieb
    Retrovirology, 12
  • [25] Characterization of HIV-1 integrase N-terminal mutant viruses
    Lloyd, Aliza G.
    Ng, Yen Shing
    Muesing, Mark A.
    Simon, Viviana
    Mulder, Lubbertus C. F.
    VIROLOGY, 2007, 360 (01) : 129 - 135
  • [26] HIV-2 Integrase Variation in Integrase Inhibitor-Naive Adults in Senegal, West Africa
    Gottlieb, Geoffrey S.
    Smith, Robert A.
    Badiane, Ndeye Mery Dia
    Ba, Selly
    Hawes, Stephen E.
    Toure, Macoumba
    Starling, Alison K.
    Traore, Fatou
    Sall, Fatima
    Cherne, Stephen L.
    Stern, Joshua
    Wong, Kim G.
    Lu, Paul
    Kim, Moon
    Raugi, Dana N.
    Lam, Airin
    Mullins, James I.
    Kiviat, Nancy B.
    Sow, Papa Salif
    PLOS ONE, 2011, 6 (07):
  • [27] In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene
    Damond, F
    Collin, G
    Matheron, S
    Peytavin, G
    Campa, P
    Delarue, S
    Taieb, A
    Bénard, A
    Chêne, G
    Brun-Vézinet, F
    Descamps, D
    ANTIVIRAL THERAPY, 2005, 10 (07) : 861 - 865
  • [28] Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
    Hutape, Hotma Martogi Lorensi
    Maladan, Yustinus
    Widodo
    HELIYON, 2018, 4 (12):
  • [29] Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants
    Smith, Robert A.
    Raugi, Dana N.
    Wu, Vincent H.
    Zavala, Christopher G.
    Song, Jennifer
    Diallo, Khardiata Mbaye
    Seydi, Moussa
    Gottlieb, Geoffrey S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [30] In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with Q151M mutation in the reverse transcriptase gene
    Damond, F
    Collin, G
    Matheron, S
    Taieb, A
    Campa, P
    Peytavin, G
    Bénard, A
    Delarue, S
    Chêne, G
    Brun-Vézinet, F
    Descamps, D
    ANTIVIRAL THERAPY, 2005, 10 : S16 - S16
12345